127 related articles for article (PubMed ID: 30890414)
1. Consumption of Movantik™ (Naloxegol) results in detection of naloxone in the patient's urine evaluated by confirmatory urine drug testing.
Haidari M; Mansani S; Ponds D; Romero L; Alsaab S
Clin Biochem; 2019 May; 67():48-53. PubMed ID: 30890414
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
Gottfridsson C; Carlson G; Lappalainen J; Sostek M
Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic Profile of Naloxegol, a Peripherally Acting
Floettmann E; Bui K; Sostek M; Payza K; Eldon M
J Pharmacol Exp Ther; 2017 May; 361(2):280-291. PubMed ID: 28336575
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.
Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):442-8. PubMed ID: 27137716
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):434-41. PubMed ID: 27137715
[TBL] [Abstract][Full Text] [Related]
6. Naloxegol: a review of its use in patients with opioid-induced constipation.
Garnock-Jones KP
Drugs; 2015 Mar; 75(4):419-25. PubMed ID: 25666542
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of naloxegol: In vitro and in vivo studies.
Costanzini A; Ruzza C; Neto JA; Sturaro C; Malfacini D; Sternini C; De Giorgio R; Calò G
Eur J Pharmacol; 2021 Jul; 903():174132. PubMed ID: 33933466
[TBL] [Abstract][Full Text] [Related]
8. Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects.
Bui K; She F; Hutchison M; Brunnström Å; Sostek M
Int J Clin Pharmacol Ther; 2015 Oct; 53(10):838-46. PubMed ID: 26329350
[TBL] [Abstract][Full Text] [Related]
9. Acute opioid withdrawal syndrome from naloxone/naloxegol interaction.
Olmo M; González-Barboteo J; Moreno D; Coma E; Serrano G
BMJ Support Palliat Care; 2021 Dec; 11(4):408-410. PubMed ID: 32788278
[TBL] [Abstract][Full Text] [Related]
10. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation.
Webster L; Diva U; Tummala R; Sostek M
Pain Pract; 2018 Apr; 18(4):505-514. PubMed ID: 28898536
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol.
Bui K; Zhou D; Sostek M; She F; Al-Huniti N
J Clin Pharmacol; 2016 Aug; 56(8):1019-27. PubMed ID: 26678015
[TBL] [Abstract][Full Text] [Related]
13. The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction.
Grønlund D; Poulsen JL; Krogh K; Brock C; Liao D; Gregersen H; Drewes AM; Olesen AE
Eur J Pharm Sci; 2018 May; 117():187-192. PubMed ID: 29432808
[TBL] [Abstract][Full Text] [Related]
14. [Opioid-induced constipation in oncologic patient: a clinical case treated with naloxegol].
Gallo P
Recenti Prog Med; 2019 Mar; 110(3):6e-9e. PubMed ID: 30968858
[TBL] [Abstract][Full Text] [Related]
15. The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol.
Bui K; She F; Zhou D; Butler K; Al-Huniti N; Sostek M
J Clin Pharmacol; 2016 Apr; 56(4):497-505. PubMed ID: 26248047
[TBL] [Abstract][Full Text] [Related]
16. An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects.
Bui K; Birmingham B; Diva U; Berger B
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):420-427. PubMed ID: 28127938
[TBL] [Abstract][Full Text] [Related]
17. Naloxegol: A Review of Clinical Trials and Applications to Practice.
Dume R; Shuman M
Orthop Nurs; 2019; 38(3):209-211. PubMed ID: 31124873
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation.
Brenner DM; Hu Y; Datto C; Creanga D; Camilleri M
Am J Gastroenterol; 2019 Jun; 114(6):954-963. PubMed ID: 31058652
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK.
Lawson R; Ryan J; King F; Goh JW; Tichy E; Marsh K
Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572
[TBL] [Abstract][Full Text] [Related]
20. Associated mood changes with naloxegol therapy for opioid-induced constipation in a patient with psychiatric disease.
Nagda N; Javed S
Pain Manag; 2022 Jan; 12(1):13-16. PubMed ID: 34284647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
